key: cord-0893398-2rh3ir0e
authors: Dhanjal, Jaspreet Kaur; Kumar, Vipul; Garg, Sukant; Subramani, Chandru; Agarwal, Shubhra; Wang, Jia; Zhang, Huayue; Kaul, Ashish; Kalra, Rajkumar Singh; Kaul, Sunil C.; Vrati, Sudhanshu; Sundar, Durai; Wadhwa, Renu
title: Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides
date: 2021-06-09
journal: Int J Biol Macromol
DOI: 10.1016/j.ijbiomac.2021.06.015
sha: f2771e3e98f2132ee9ceb8b92b61d29dd0cc5a50
doc_id: 893398
cord_uid: 2rh3ir0e

COVID-19 caused by SARS-CoV-2 corona virus has become a global pandemic. In the absence of drugs and vaccine, and premises of time, efforts and cost required for their development, natural resources such as herbs are anticipated to provide some help and may also offer a promising resource for drug development. Here, we have investigated the therapeutic prospective of Ashwagandha for the COVID-19 pandemic. Nine withanolides were tested in silico for their potential to target and inhibit (i) cell surface receptor protein (TMPRSS2) that is required for entry of virus to host cells and (ii) viral protein (the main protease M(pro)) that is essential for virus replication. We report that the withanolides possess capacity to inhibit the activity of TMPRSS2 and M(pro). Furthermore, withanolide-treated cells showed downregulation of TMPRSS2 expression and inhibition of SARS-CoV-2 replication in vitro, suggesting that Ashwagandha may provide a useful resource for COVID-19 treatment.

polyprotein at multiple conserved sites after the autolytic cleavage of itself from pp1a and pp1ab [13] . The importance of M pro in the infection cycle of virus and absence of proteins homologous to this enzyme in the host cell, make M pro also an attractive target for developing antiviral therapies [14] . M pro from different human and animal coronaviruses possess high similarity in terms of primary amino acid sequence and the functional tertiary structure. The antiviral drugs designed for M pro are mainly targeted to its highly conserved substrate binding pocket [15] . Similar to other coronaviruses, SARS-CoV-2 also shares this homology in its M pro enzyme. Several key identical residues at the various sub-sites of substrate binding pocket of M pro of different coronaviruses including SARS-CoV-2 have been reported [16] .

These conserved residues mainly include His41, Tyr54, His163, Glu166, His172, Asp187 and Gln192.

Various strategies to inhibit TMPRSS2 and M pro , and its potential for management of COVID-19 have been reported and discussed here. Peptide-conjugated phosphorodiamidate morpholino oligomers that sterically blocked TMPRSS2 transcription has been reported to significantly suppress the viral titers [17] . BAPA (benzylsulfonyl-d-arginine-proline-4amidinobenzylamide), a potent inhibitor of HAT and TMPRSS2 has also been shown to strongly affect the virus propagation [18, 19] . Camostat mesylate, a clinically proven and commercially available serine protease inhibitor, in use for the treatment of oral squamous cell carcinoma [20] , dystrophic epidermolysis [21] , exocrine pancreatic enzyme inhibition [22, 23] , and chronic pancreatitis [24, 25] , has also been suggested as a candidate antiviral drug. It has been shown to suppress infection of SARS-CoV and human coronavirus NL63 in HeLa cells that express ACE2 and TMPRSS2 proteins [26] . Camostat was shown to partially block the entry of MERS-CoV into TMPRSS2 expressing Vero cells, effect of which was enhanced on the simultaneous use of inhibitors of cathepsin L. Of note, Camostat was shown to suppress the entry of MERS-CoV into Calu-3 cells by 10-fold that led to 270-fold decrease downregulate the expression of TMPRSS2 [44] . We have also reported Wi-N to be a potential inhibitor of SARS-CoV-2 M pro protein [16] . In the present study, we examined the potential of several withanolides for their ability to (i) block the interaction of SARS-CoV-2 with host cells receptor (TMPRSS2) and downregulate the expression of TMPRSS2 at the mRNA and protein levels, and (ii) interact at the substrate binding site of main protease (M pro treatment, we tested their anti-viral potential in a cell-based assay and found that the most withanolides, although to a variable extent (ranging from 17 to 84%) caused inhibition of infection as determined by RT-PCR amplification of viral envelope and nucleocapsid sequences. We also report here that the water-based Ashwagandha extracts, containing a mixture of withanolides, may provide a useful resource for COVID-19 treatment.

The crystal structure of TMPRSS2 is not yet available in the Protein Data Bank, hence its modeled structure was retrieved from the Swiss model repository (ID: O15393). The structure was modeled based on another homologous Transmembrane class II family protein, Serine protease hepsin. The identity between the sequence of TMPRSS2 and hepsin is 33 .82%, and the Q mean of the modeled structure has been reported to be -1.62, which is an indicative of a good quality modelled structure. The catalytic domain in both the proteins was found to be well conserved with His296, Asp345 and Ser441 as functional residues [45] .

Further, the structure of M pro complexed with a peptide-like inhibitor N3 was retrieved from the PDB (6LU7) [30] . These structures were optimized and prepared for docking studies using the protein preparation wizard of the Schrodinger suite [46] . Preparation of the structure included the removal of water molecules, addition of polar hydrogen atoms, filling of missing amino acid side chains and minimization of the structure using the OPL3e force field [47] .

The structure of Camostat mesylate (CID-5284360) and various withanolides- [46, 48] . This preparation mainly included the generation of ionization states at pH 7±2 using the Epik program, desalting of the ligands, generation of tautomers and stereoisomers while retaining the specific chiralities and minimization of the generated ligand structures using OPL3e forcefield [47, 49] .

The key catalytic residues of TMPRSS2 involved in the proteolytic activity have been reported as His296, Asp345 and Ser441 [50, 51] . The 20 Å 3 grid for docking with TMPRSS2 was generated taking its catalytic residues-His296, Asp345 and Ser441 as the centroid. In case of M pro , the grid of 20 Å 3 was generated by covering the residues making polar contacts with N3 inhibitor in the native crystal structure of M pro that mainly involved Phe140, Asn142, Gly143, His164 and Glu166. The Glide module of Schrodinger was used for the extra precision (XP) flexible docking of the ligands at the generated grid sites [46, 52] .

To investigate the stability of binding and interactions between the proteins and ligands, the docked complexes were subjected to MD simulations. The MD simulations were done using J o u r n a l P r e -p r o o f the Desmond tool integrated with the maestro of the Schrodinger suite [46, 47, 53] . Firstly, the systems were built, in which the docked complexes were solvated with TIP3P water model. Appropriate number of ions ( Na + /Cl -) were then added to neutralize these systems enclosed in the orthorhombic periodic boundary boxes.. The energy of the prepared systems was minimized by running 100 ps low-temperature (10K) Brownian motion MD simulation in NVT ensemble to remove steric clashes and move the system away from an unfavourable high-energy conformation. The systems were further relaxed using default parameters of 'relax system before simulation' option of Desmond, The equilibrated systems were then subjected to 100 ns simulation in NPT ensemble with 300 K temperature maintained by Nose-Hoover chain thermostat, constant pressure of 1atm maintained by Martyna-Tobias-Kelinbarostat, the time step of 2fs, and recording interval of 20 ps.

The generated MD simulation trajectories were visualized and analyzed using the system event analysis and simulation interaction diagram tools. To account for the stability of the simulated complexes, the global deviation or the Root Mean Square Deviation (RMSD) in the structures with reference to initial docked structures throughout the simulation run was analyzed. The Root Mean Square Fluctuation (RMSF) was also calculated to investigate the average fluctuation in the amino acid residues of the apo proteins and their complexes with different ligands. As hydrogen bonds are crucial in determining the specificity and affinity of a drug towards its receptor, we next calculated the average number of the hydrogen bonds formed during the simulation time for each protein-ligand complex [54] . Furthermore, to investigate the significant interactive residues of the proteins, which were making contact with the ligands during the MD simulation, the polar and non-polar interactions, as well as the occupancy time of those interactions was calculated. Finally, the MM/GBSA (molecular mechanics energies combined with the generalized Born and surface area continuum solvation) free binding energy was calculated using the prime module of the Schrodinger J o u r n a l P r e -p r o o f suite [46, 55] to determine the binding affinity of the ligands towards TMPRSS2. A hundred frames equally spanned between 40-100 ns of the trajectory were used for this computation using the following equation:

MM/GBSA ΔG bind = ΔG complex -(G receptor + G ligand ) ΔG = ΔE gas + ΔG sol − TΔS gas ΔE gas = ΔE int + ΔE elec +ΔE vdw ΔG sol = ΔG gb + ΔG surf The prime module of Schrodinger software was used to compute all the energy components using the coordinates of complex, receptor and ligand using OPL3e forcefield. The binding free energy (ΔG bind ) can be dissociated into the binding free energy of the complex (ΔG complex ), receptor (ΔG receptor ) and ligand (ΔG ligand ). The gas-phase interaction energy (ΔE gas ) was calculated as the sum of electrostatic (ΔE elec ) and van der waal (ΔE vdw ) interaction energies, while internal energy term was neglected. The solvation free energy (ΔG sol ) contains non-polar (ΔG surf ) and polar solvation energy (ΔG gb ), which was calculated using the VSGB solvation model and OPL3e force field, neglecting the entropy factor.

Human-derived esophageal squamous carcinoma (T.Tn), human breast carcinoma (MCF7), non-small lung cancer (A549), and tongue oral squamous carcinoma (HSC3) cell lines were procured from the Japanese Collection of Research Bioresources (JCRB) Cell Bank, Japan. 

Short-term QCV: A total of 1x10 5 cells per well were plated in a 12-well plate and allowed to settle overnight, followed by treatment with each of the withanolides. The control or treated cells were incubated at 37°C and 5% CO 2 . After 48 h, cells were fixed with acetone: methanol (1:1), stained with Crystal Violet (CV), and de-stained into the solution, which was quantified by the help of a spectrophotometer at 570 nm. Statistical significance was calculated by an unpaired t-test of Microsoft Excel® software (2016).

Long-term QCV: 100 cells per well were plated in a 12-well plate and allowed to settle overnight, followed by treatment with each of the withanolides. The control or treated cells were incubated at 37°C and 5% CO 2 , and the withanolide-supplemented medium was replaced every alternate day. After 9 days, cells were fixed, stained, and de-stained into the solution, which was quantified by the help of a spectrophotometer as described in the earlier section. Statistical significance was calculated by an unpaired t-test of Microsoft Excel software (2016).

J o u r n a l P r e -p r o o f

A total of 2x10 5 cells per well were plated in a 6-well plate, allowed to settle overnight, followed by treatment with each of the withanolides. The control or treated cells were incubated at 37°C and 5% CO 2 . After 48 h, the cells were harvested from the petri dishes and lysed with Trizol (Ambion®, Foster City, CA, USA, 15596018) at room temperature for 5 min, segregated in chloroform (Wako, Tokyo, Japan, 038-02606) at room temperature for 5 min, centrifuged at 12,000 rpm for 15 min and supernatant was separated. The supernatant was then washed in isopropanol (Wako, 166-04836) at room temperature for 10 min, centrifuged at 12,000 rpm for 15 min and pellet was washed in 70% ice-cold ethanol and centrifuged at 8000 rpm for 5 min twice, followed by air-drying and resuspension in nuclease-free water to extract the pure RNA. The concentration and quality of RNA was evaluated through a spectrophotometer (ND-1000, Nanodrops, Wilmington, NC, USA). The cDNA was prepared using a reverse transcription kit (Qiagen, Hilden, Germany, 205313) following the manufacturer's instructions. The master mix for amplification was prepared by mixing 1 µL cDNA with 0.1 µL Ex Taq (Takara, Kusatsu, Shiga, Japan, RR001), 2 µL 10X TAQ buffer, 2 µL dNTP, 1 µL each of forward and reverse primers (indicated earlier) in 12.9 µL nuclease free water and amplified using 'denaturation = 95°C, 10 min  amplification = 95°C, 45s -60°C, 1 min -72°C, 45s (35~37 cycles)  annealing = 72°C, 10min  4°C' protocol. The amplified products were resolved on a 1% agarose gel containing 0.0625 µg/mL EtBr (Ethidium Bromide; Invitrogen, 15585-011), and image was acquired using a Lumino Image Analyzer (LAS3000-mini; Fuji Film, Tokyo, Japan) equipped with a CCD (charge-coupled device) camera. Band intensity was quantified using ImageJ software (NIH) and plotted as a percentage using Microsoft™ Office 2016. 417bp; Tm-60°C.

A total of 2.5x10 5 cells per well were plated in a 6-well plate, allowed to settle overnight, visualized using a Lumino Image Analyzer (LAS 3000-mini; Fuji Film, Tokyo, Japan). Band intensity was quantified using ImageJ software (NIH) and plotted as a percentage using Microsoft™ Office 2016.

Cells (5x10 4 ) were seeded on 18-mm glass coverslips, placed in 12-well plates and cultured for 24 h in a humidified incubator (37°C and 5% CO 2 ) for attachment. The cells were then treated with the withanolides or extracts for 24 h. The cells were then washed with PBS and fixed with methanol: acetone (1:1) at 4C for 10 min. After that, fixation solution was removed, and cells were again washed with PBS and permeabilized by PBST for 10 min.

After permeabilization, the glass coverslips were blocked for an hour with 2% bovine serum Oberkochen, Germany).

The assay was done in a 96-well plate in triplicates for each sample. A total of 1x10 4 Vero E6 Ct values for N and E gene sequence detection were determined and used for calculating the percent virus inhibition with respect to the control.

Statistical significance was calculated by an unpaired t-test of GraphPad software (2018-2019) (GraphPad, San Diago, CA, USA) using mean, SD (standard deviation), and N (number) from three independent experiments, and shown as *p<0.05, **p<0.01, ***p<0.001 or ns = not significant.

In order to explore the therapeutic potential of Ashwagandha in the current COVID-19

pandemic, we considered host cell surface protein TMPRSS2, which facilitates the process of virus entry to the cells, as the target. Ashwagandha-derived nine withanolides were examined for their ability to (a) interact with/block, and (b) reduce TMPRSS2 expression using (i) molecular docking and computational analyses, and (ii) mRNA and protein expression in control and withanolide-treated cells, respectively.

Camostat mesylate is a known inhibitor of TMPRSS2. It was thus used as a reference molecule for molecular docking analysis. At first, we estimated the binding affinity of the other withanolides can also be suggested to have the potential to block the interaction between SARS-CoV-2 and TMPRSS2.

predicted Withanoside-V as the best among all the withanolides N3, a synthetic peptidomimetic compound has been reported to target the substrate binding pocket of the main protease across different variants of coronavirus including SARS-CoV-2 [30, 56] . We first estimated the docking score for the N3 inhibitor bound to M pro at the same site as in PDB 6LU7, which was found to be -5.68 kcal/mol. The N3 inhibitor was making hydrogen bonds with Glu166 and Thr190 of M pro . Among all the withanolides, Withanoside-V docked with M pro with a score of -10.10 kcal/mol, which was almost double the docking score for the N3 inhibitor. The docking score for other withanolides was also comparable to that of N3 inhibitor. The best-docked pose for all the M pro -ligand complexes showing the hydrogen bonded interactions is illustrated in Fig. 3 , while all the polar and non-polar interactions of best-docked pose along with docking scores, has been summarized in Table 3 .

In order to further look into the binding affinity and the stability of the docked ligands, we previous reports as well [16] . No significant fluctuations were observed in the RMSD of these ligands just after 10 ns of simulation time (Supplementary Fig. 3A ). All the interacting M pro -ligand complexes got stable within 10 ns of the simulation (Supplementary Fig. 3B ).

The RMSF plot showed that all the complexes along with the Apo form of M pro had similar flexibility/fluctuation of amino acid residues, and overall, these fluctuations were less than 2.5 Å in each of the system (Supplementary Fig. 3C ). Next, we investigated the hydrogen bonding pattern for all these complexes. We found that N3 inhibitor was forming the highest number of the hydrogen bonds Table 4 . This data thus suggests the potential of these withanolides as possible inhibitors of the main protease of SARS-CoV-2.

Next, we performed cell-based TMPRSS2 expression screening for the withanolides. We first with Withanone (Fig. 5C) . Consistent with the Western blotting results, we observed decrease in TMPRSS2 protein in treated cells by immunostaining (Fig. 5D ). The expression of TMPRSS2 has been reported to vary among different tissues/organs [58, 59] . To account for this variation and to examine that the effect of withanolides is not dependent on cell lines used, we performed the same analyses in two more cell lines i.e., A549 and MCF7. All the five withanolides -Withaferin-A, Withanone, Withanolide-A, Withanoside-IV and Withanoside-V, caused decrease in the mRNA levels of TMPRSS2 in both the cell lines.

TMPRSS2 protein was also found to be less in the treated cells in comparison to the control group ( Supplementary Fig. 6 ).

We then tested the different withanolides for their ability to inhibit SARS-CoV-2 replication in Vero E6 cells. As shown in Table 5 

Based on the above data showing that cells treated with different withanolides showed significant downregulation of TMPRSS2, and most of these withanolides showed potential to block activitiy of TMPRSS2 and M pro ,, we predicted that the extracts enriched in withanolides may provide an easy and economic source to block entry of corona virus to host cells as well as inhibit its replication. We have earlier optimized the extraction of two of the major withanolides-Withaferin-A and Withanone using cyclodextrin [60] . As reported earlier, leaves possess highest content of withanolides; whereas stem possesses a relatively high ratio J o u r n a l P r e -p r o o f of Withanone [60] [61] . We prepared leaf and stem extracts [60] , and investigated the content of 8 withanolides. As shown in Fig. 5E , along with Withaferin A and Withanone, we detected Withanolide IV, Withanolide V and 12-deoxywithastramonolide in water soluble and insoluble extracts of leaves. 12-deoxywithastramonolide was also detected in stem extracts.

We next examined TMPRSS2 expression in the extract (non-toxic concentration, as determined by short and long term MTT assays; Supplementary Fig. 5 )-treated cells. As shown in Fig. 5F -H, the extracts caused downregulation of TMPRSS2 expression at both transcriptional (Fig. 5F ) and translational levels (Figs. 5G and 5H), thereby suggesting the possible use of extracts as an effective alternative to the pure Ashwagandha-derived compounds. and had also been reported in our previous study [44] . TMPRSS2 is enriched in cancer cells (especially in case of pancreatic cancer) and has been considered as a anti-cancer drug target [5, 8, 48, 50, 51] . The downregulation of TMPRSS2 in Withanolide-treated cells may also account for anti-cancer potential of Withanolides. Withanone has earlier been shown to cause activation of tumor suppressor pathways and inhibit cancer cell proliferation [36] [37] [38] [39] [40] [41] [42] [43] Ashwagandha extracts containing a natural mixture of withanolides also caused a significant reduction of TMPRSS2 mRNA in treated cells, and thus is proposed as a candidate resource for COVID-19 treatment, warranting further laboratory and clinical studies.

The 

Data last updated: 2020/10/16

Global patterns in coronavirus diversity

Epidemiology, genetic recombination, and pathogenesis of coronaviruses

Structural insights into coronavirus entry

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Phenotypic analysis of mice lacking the Tmprss2-encoded protease

TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections

MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in China

Conservation of substrate specificities among coronavirus main proteases

An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: J o u r n a l P r e -p r o o f Journal Pre-proof peptidomimetics and small molecule chemotherapy

Coronavirus genomics and bioinformatics analysis

Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity

Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2

Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections

Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium

Clinical experience with a protease inhibitor [N, Ndimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma

Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa: in vitro effect and clinical trial with camostat mesylate

Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and J o u r n a l P r e -p r o o f Journal Pre-proof exocrine pancreatic secretion

Stimulation of pancreatic secretion in man by a protease inhibitor (camostate)

Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease

A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms

Nf-κb-Dependent inhibition of HIV-1 transcription by withaferin A, HIV

Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the antiherpetic mode of action of herbal drug withaferin A

Promising anti-influenza properties of active constituent of Withania somnifera ayurvedic herb in targeting neuraminidase of J o u r n a l P r e -p r o o f Journal Pre-proof H1N1 influenza: computational study

Ashwagandha derived withanone targets TPX2-Aurora A complex: computational and experimental evidence to its anticancer activity

Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence

Selective killing of cancer cells by leaf extract of Ashwagandha: identification of a tumorinhibitory factor and the first molecular insights to its effect

Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences

Wild type p53 function in p53(Y220C) mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence

Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling

Withanone-rich combination of Ashwagandha withanolides restricts metastasis and angiogenesis through hnRNP-K

Molecular insights into Withaferin-A-induced senescence: Bioinformatics and experimental evidence to the role of NFkappaB and CARF

Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells

Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia

Protein Preparation Wizard, Prime, Desmond Molecular Dynamics System

OPLS3: A force field providing broad coverage of drug-like small molecules and proteins

Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution

Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, J o u r n a l P r e -p r o o f Journal Pre-proof and SRCR domains and maps to 21q22

The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells

Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein− ligand complexes

Scalable algorithms for molecular dynamics simulations on commodity clusters, SC'06: Proc. 2006 ACM/IEEE Conference on Supercomputing

The role of hydrogen-bonds in drug binding

A hierarchical approach to all-atom protein loop prediction

Structure of main protease from human coronavirus NL63: Insights for wide spectrum anti-coronavirus drug design

Integration of conventional cell viability assays for reliable and reproducible read-outs: experimental evidence

ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Novel methods to generate active ingredientsenriched Ashwagandha leaves and extracts

Organic cultivation of Ashwagandha with improved biomass and high content of active withanolides: Use of vermicompost

Natural product-derived phytochemicals as potential agents against coronaviruses: A review

Natural products as potential leads against coronaviruses: Could they be encouraging structural models against SARS-CoV-2?

Potential use of polyphenols in the battle against COVID-19

Roles of flavonoids against coronavirus infection

Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach

Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-J o u r n a l P r e -p r o o f -5

M pro -Withanoside-IV -6.39 Phe140, Leu141, Cys145

Acknowledgements. This study was supported by the funds granted by AIST (Japan) and DBT (Government of India) grant no. BT/BI/14/042/2017. Authors thank Priyanshu Bhargava for valuable help.